Pemetrexed disodium in ovarian cancer treatment

Expert Opinion on Investigational Drugs

Volumn 21, Issue 4, 2012, Pages 437-449

  Morotti, M ^a   Valenzano Menada, M ^a   Venturini, P L ^a   Mammoliti, S ^a   Ferrero, S ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Antimetabolite; Multitargeted antifolate; Ovarian cancer; Pemetrexed; Recurrent disease

Indexed keywords

CARBOPLATIN; CYANOCOBALAMIN; DOXORUBICIN; FOLIC ACID; GEMCITABINE; PEMETREXED;

ANEMIA; AREA UNDER THE CURVE; ASTHENIA; ATAXIA; BONE MARROW SUPPRESSION; DIARRHEA; DIZZINESS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; EMBASE; FATIGUE; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MEDLINE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVARY CANCER; PHARMACOGENOMICS; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VITAMIN SUPPLEMENTATION; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; CLINICAL TRIALS AS TOPIC; FEMALE; GLUTAMATES; GUANINE; HUMANS; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84858274224     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.661714     Document Type: Review

References (78)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
2. Boyle P, Ferlay J. Cancer incidence and mortality in Europe 2004. Ann Oncol 2005;16:481-8 (Pubitemid 40458328)
3. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011;61:183-203
4. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 6th Annual Report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006;95:161-92
5. Colombo N, Peiretti M, Parma G, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21:23-30
6. Harter P, Hilpert F, Mahner S, et al. Role of cytoreductive surgery in recurrent ovarian cancer. Expert Rev Anticancer Ther 2009;9:917-22
7. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003;3:502-16 (Pubitemid 37328838)
8. Wagner C. Biochemical role of folate in cellular metabolism. Folate in Health and Disease; Marcel Dekker New York: 1995
9. Parmar MKLJ, Colombo N, du Bois A, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099-106
10. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006;24:4699-707 (Pubitemid 46630933)
11. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007;25:2811-18 (Pubitemid 47123191)
12. Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008;26:890-6 (Pubitemid 351398081)
13. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010;28:3323-9
14. Ozols RF. Treatment goals in ovarian cancer. Int J Gynecol Cancer 2005;15(Suppl 1):3-11 (Pubitemid 40696471)
15. Colombo N, Gore M. Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy. Crit Rev Oncol Hematol 2007;64:129-38 (Pubitemid 47496221)
16. Naumann RW, Coleman RL. Management strategies for recurrent platinum-resistant ovarian cancer. Drugs 2011;71:1397-412
17. Abushahin F, Singh DK, Lurain JR, et al. Weekly topotecan for recurrent platinum resistant ovarian cancer. Gynecol Oncol 2008;108:53-7 (Pubitemid 350299419)
18. Vandenput I, Amant F, Neven P, et al. Effectiveness of weekly topotecan in patients with recurrent epithelial ovarian cancer. Int J Gynecol Cancer 2007;17:83-7 (Pubitemid 46213974)
19. Gordon AN, Granai CO, Rose PG, et al. Phase II study of liposomal doxorubicin in platinum-and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000;18:3093-100
20. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-22 (Pubitemid 32642183)
21. Naumann RW, Symanowski JT, Ghamande SA, et al. PRECEDENT: a randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum resistant ovarian cancer. J Clin Oncol 2010;28:LBA5012b
22. Bailey LB, Gregory JF III. Folate metabolism and requirements. J Nutr 1999;129:779-82 (Pubitemid 29162370)
23. Rustum YM, Harstrick A, Cao S, et al. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol 1997;15:389-400 (Pubitemid 27020596)
24. Farber S, Diamond LK, Mercer RD, et al. Temporary remission in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl glutamic acid (aminopterin). N Engl J Med 1948;238:787-93
25. Hagner N, Joerger M. Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res 2010;2:293-301
26. Rollins KD, Lindley C. Pemetrexed: a multitargeted antifolate. Clin Ther 2005;27:1343-82 (Pubitemid 41599884)
27. Zhao R, Matherly LH, Goldman ID. Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev Mol Med 2009;11:e4
28. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 1994;73:2432-43 (Pubitemid 24129130)
29. Qiu A, Jansen M, Sakaris A, et al. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 2006;127:917-28 (Pubitemid 44792250)
30. Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene 2003;22:7537-52 (Pubitemid 37487175)
31. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d] pyrimidinebased antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-23 (Pubitemid 27138611)
32. Goldman ID, Zhao R. Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin Oncol 2002;29(Suppl 18):3-17 (Pubitemid 36176669)
33. Pizzorno G, Moroson BA, Cashmore AR, et al. Multifactorial resistance to 5,10 dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM. Cancer Res 1995;55:566-73
34. Rhee MS, Ryan TJ, Galivan J. Glutamyl hydrolase and the multitargeted antifolate LY231514. Cancer Chemother Pharmacol 1999;44:427-32 (Pubitemid 29455590)
35. de Jonge MJ, Punt CJ, Sparreboom A, et al. Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors. J Clin Oncol 2002;20:1923-31 (Pubitemid 34273285)
36. Rinaldi DA, Burris HA, Dorr FA, et al. Initial phase I evaluation of the novel thymidylate synthase inhibitor LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 1995;13:2842-50
37. McDonald AC, Vasey PA, Adams L. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin Cancer Res 1998;4:605-10 (Pubitemid 28193558)
38. Rinaldi DA, Kuhn JG, Burris HA, et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 1999;44:372-80 (Pubitemid 29455582)
39. Latz JE, Chaudhary A, Ghosh A, et al. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother Pharmacol 2006;57:401-11 (Pubitemid 43087583)
40. Sørensen JB. Pharmacokinetic evaluation of pemetrexed. Expert Opin Drug Metab Toxicol 2011;7:919-28
41. Eli Lilly and Co. ALIMTA (pemetrexcd disodium) injection, powder, lyophillized. for solution Tor intravenous use: US prescribing information [online]. Available from: http://pi. lilly.com/us/alimta-pi.pdf [Accessed 20 July 2009]
42. Dickgreber NJ, Diaz Padilla I, Paz-Ares LG, et al. Th. safety and pharmacokinetics (PK.) of pemetrexed (PEM) in patients with third-space fluid (TSF). J Clin Oncol 2008;26:2555
43. Hughes A, Calvert P, Azzabi A, et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 2002;20:3533-44
44. Dickgreber NJ, Fink TH, Latz JE, et al. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer. Clin Cancer Res 2009;15:382-9
45. Hanauske A, Chen V, Paoletti P, et al. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 2001;6:363-73 (Pubitemid 32816541)
46. Hammond L, Villalona-Calero M, Eckhardt G, et al. A Phase I and pharmacokinetic (PK) study of the multitargeted antifolate (MTA) LY231514 with folic acid. Proc Am Soc Clin Oncol 1998;17:225
47. Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002;1:545-52
48. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44 (Pubitemid 46606305)
49. Rinaldi DA. Overview of phase I trials of multitargeted antifolate (MTA, LY231514). Semin Oncol 1999;26:82-8 (Pubitemid 29218033)
50. US Food and Drug Administration Center for Drug Evaluation and Research. Alimta. Available from: http:/www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 021462s018s021s022lbl.pdf [Last accessed November 2009]
51. European Medicines Agency. Summary of Product Characteristics. Alimta. Available from: http://www.emea.europa. eu/humandocs/Humans/EPAR/alimta/alimta. htm [Last accessed November 2009]
52. Gridelli C, Maione P, Rossi A, et al. Pemetrexed in advanced non-small cell lung cancer. Expert Opin Drug Saf 2011;10:311-17
53. Scagliotti G, Brodowicz T, Shepherd FA, et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 2011;6:64-70
54. Toffoli G, Russo A, Gallo A, et al. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer 1998;79:121-6 (Pubitemid 28201681)
55. Corona G, Giannini F, Fabris M, et al. Role of folate receptor and reduced folate carrier in the transport of 5-methyltetrahydrofolic acid in human ovarian carcinoma cells. Int J Cancer 1998;75:125-33 (Pubitemid 28113987)
56. Markert S, Lassmann S, Gabriel B, et al. Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. Anticancer Res 2008;28:3567-72
57. Crane LM, Arts HJ, van Oosten M, et al. The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer. Cell Oncol (Dordr) 2011; [Epub ahead of print]
58. Kalli KR, Oberg AL, Keeney GL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 2008;108:619-26
59. Matherly L, Hou Z, Deng Y. Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev 2007;26:111-28 (Pubitemid 46452186)
60. Miotti S, Bagnoli M, Ottone F, et al. Simultaneous activity of two different mechanisms of folate transport in ovarian carcinoma cell lines. J Cell Biochem 1997;65:479-91 (Pubitemid 27240914)
61. Hensley ML, Larkin J, Fury M, et al. A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer. Clin Cancer Res 2008;14:6310-16
62. Sehouli J, Camara O, Mahner S, et al. A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer. Cancer Chemother Pharmacol 2010;66:861-8
63. Richards DA, Loesch D, Vukelja SJ, et al. Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer. Invest New Drugs 2011;29:963-70
64. Matulonis UA, Horowitz NS, Campos SM, et al. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol 2008;26:5761-6
65. Vergote I, Calvert H, Kania M, et al. A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur J Cancer 2009;45:1415-23
66. Miller DS, Blessing JA, Krasner CN, et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol 2009;27:2686-91
67. Gasent-Blesa JM, Alberola Candel V, Provencio Pulla M, et al. Management of platinum-resistant ovarian cancer with the combination of pemetrexed and gemcitabine. Clin Transl Oncol 2009;11:35-40
68. Mey V, Giovannetti E, De Braud F, et al. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Br J Cancer 2006;95:289-97 (Pubitemid 44187589)
69. Giovannetti E, Mey V, Danesi R, et al. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 2004;10:2936-43 (Pubitemid 38619668)
70. Sehouli J, Alvarez AM, Manouchehrpour S, et al. A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer. Gynecol Oncol 2011; [Epub ahead of print]
71. LoRusso PM, Boerner SA, Seymour L. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics. Clin Cancer Res 2010;16:1710-18
72. Adjei AA, Mandrekar SJ, Dy GK, et al. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol 2010;28:614-19
73. Argiris A, Karamouzis MV, Gooding WE, et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 2011;29:1140-5
74. Vella N, Aiello M, Russo AE, et al. 'Genetic profiling' and ovarian cancer therapy (Review). Mol Med Rep 2011;4:771-7
75. Takezawa K, Okamoto I, Okamoto W, et al. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer 2011;104:1594-601
76. Smit EF, Burgers SA, Biesma B, et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2009;27:2038-45
77. Gusella M, Padrini R. G > C SNP of thymidylate synthase with respect to colorectal cancer. Pharmacogenomics 2007;8:985-96 (Pubitemid 47423688)
78. Available from: http://clinicaltrials.gov/ct2/results?term= pemetrexed+ovarian